Response to "Reply to: 'The decreasing predictive power of MELD in an era of changing etiology of liver disease'"

被引：0
|
作者：
Godfrey, Elizabeth L. [1 ]
Malik, Tahir H. [1 ]
Lai, Jennifer C. [2 ]
Mindikoglu, Ayse L. [1 ,3 ]
Galvan, N. Thao N. [1 ]
Cotton, Ronald T. [1 ]
O'Mahony, Christine A. [1 ]
Goss, John A. [1 ]
Rana, Abbas [1 ]
机构：
[1] Baylor Coll Med, Michael E DeBakey Dept Surg, Div Abdominal Transplantat, Houston, TX 77030 USA
[2] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA
[3] Baylor Coll Med, Margaret M & Albert B Alkek Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2020年 / 20卷 / 03期
关键词：
classification systems; Model for End-Stage Liver Disease (MELD); clinical research; practice; health services and outcomes research; liver transplantation; hepatology; organ allocation; organ procurement and allocation; patient survival; registry; registry analysis; waitlist management; MODEL; SURVIVAL;
D O I：
10.1111/ajt.15783
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：903 / 904
页数：2
相关论文
共 50 条
  • [31] The model for end-stage liver disease (MELD) score is predictive of intensive care unit (ICU) mortality in patients with cirrhosis
    Massoumi, Ali
    Hafi, Muhannad
    Lu, Amy
    Johnson, Lynt B.
    Shetty, Kirti
    HEPATOLOGY, 2006, 44 (04) : 467A - 467A
  • [32] ACG Clinical Guideline for Alcoholic Liver Disease: The MELD Threshold for Corticosteroid Treatment has Yet to be Established Response
    Singal, Ashwani K.
    Bataller, Ramon
    Ahn, Joseph
    Kamath, Patrick S.
    Shah, Vijay H.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 (01): : 176 - 176
  • [33] Response to the changing epidemiology of meningococcal disease in North America 1945-2010 Reply
    Baccarini, Carmen
    Ternouth, Andrew
    Wieffer, Heather
    Vyse, Andrew
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (06) : 1325 - 1325
  • [34] Clinical Relevance of Kidney Biopsy in Patients Qualified for Liver Transplantation and After This Procedure in the Model for End-stage Liver Disease (MELD) Era: Where Are We Today?
    Wieliczko, Monika
    Oldakowska-Jedynak, Urszula
    Malyszko, Jolanta
    ANNALS OF TRANSPLANTATION, 2020, 25 : 1 - 10
  • [35] Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016
    Kim, Donghee
    Li, Andrew A.
    Gadiparthi, Chiranjeevi
    Khan, Muhammad Ali
    Cholankeril, George
    Glenn, Jeffrey S.
    Ahmed, Aijaz
    GASTROENTEROLOGY, 2018, 155 (04) : 1154 - +
  • [36] CHANGING TRENDS IN ETIOLOGY-BASED CHRONIC LIVER DISEASE FROM 2000 THROUGH 2019 IN MEXICO: MULTICENTER STUDY
    Gonzalez Chagolla, Alex
    Olivas-Martinez, Antonio
    Valenzuela-Vidales, Karen
    Diaz-Garcia, Juan D.
    Cordova-Gallardo, Jacqueline
    Garcia-Juarez, Francisco I.
    Romero-Lozania, Jose A.
    Gonzalez Huezo, Maria Sarai
    Milanes-Lizarraga, Guadalupe
    Paez-Zayas, Victor M.
    Chavez-Garcia, Luis C.
    Juarez-Leon, Oscar A.
    Toapanta-Yanchapaxi, Liz
    Sanchez-Avila, Francisco
    Garcia Juarez, Ignacio
    HEPATOLOGY, 2020, 72 : 383A - 384A
  • [37] Mortality and AKI Severity in Cirrhosis: Model for End-Stage Liver Disease Score and Bilirubin Predictive, HRS-1 as AKI Etiology Not Predictive
    Sultan, Mohammad T.
    Varghese, Vipin
    Chalmers, Dustin
    Cacioppo, Paula A.
    Velez, Juan Carlos Q.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 66 - 67
  • [38] Screening of esophagogastric varices: Performance of the "Expanded Baveno VI criteria" and the "platelet 150/MELD 6" strategy in all etiology compensated advanced chronic liver disease
    Tosetti, G.
    Mura, V. L.
    D'ambrosio, R.
    Degasperi, E.
    Mezzina, N.
    Vigano, M.
    Rumi, M. G.
    Fracanzani, A. L.
    Lombardi, R.
    Fraquelli, M.
    Aghemo, A.
    Lampertico, P.
    Primignani, M.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S734 - S735
  • [39] Screening of esophagogastric varices: Performance of the "Expanded Baveno VI criteria" and the "platelet 150/MELD 6" strategy in all etiology compensated advanced chronic liver disease
    Tosetti, G.
    La Mura, V.
    D'Ambrosio, R.
    Degasperi, E.
    Mezzina, N.
    Vigano, M.
    Rumi, M.
    Fracanzani, A. L.
    Lombardo, R.
    Fraquelli, M.
    Aghemo, A.
    Lampertico, P.
    Primignani, M.
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (01) : 59 - 59
  • [40] Trials on preoperative chemotherapy in resectable colorectal liver metastases need prospective evaluation of predictive factors of response - In reply
    Gruenberger, Thomas
    Gruenberger, Birgit
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) : 3813 - 3813
12345